INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a multicenter phase 1 trial of INCB7839 for children with recurrent or progressive
high-grade gliomas, including, but not limited to, diffuse intrinsic pontine glioma (DIPG)
and other diffuse midline gliomas (DMGs), after upfront therapy.